1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. 発作タイプ別スニペット
3.2. 治療タイプ別スニペット
3.3. エンドユーザー別スニペット
3.4. 地域別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. てんかん罹患率の上昇、事故および脳損傷の増加
4.1.1.2. XX
4.1.2. 阻害要因
4.1.2.1. 抗てんかん薬に伴う副作用
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
6. 発作タイプ別
6.1. はじめに
6.1.1. 発作タイプ別市場規模分析および前年比成長率分析（%） 6.1.2.
6.1.2. 市場魅力度指数（発作タイプ別
6.2. 原発性/全般性発作
6.2.1. はじめに
6.2.2. 市場規模分析と前年比成長率分析(%)
6.3. 部分/局所発作
7. 治療タイプ別
7.1. はじめに
7.1.1. 治療タイプ別市場規模分析および前年比成長率分析（%） 7.1.2.
7.1.2. 市場魅力度指数（治療タイプ別
7.2. 薬剤タイプ別
7.2.1. 導入剤
7.2.2. 市場規模分析と前年比成長率分析(%)
7.2.3. ビガバトリン
7.2.4. フェンフルラミン
7.2.5. ルフィナミド
7.2.6. ガナキソロン
7.2.7. スチリペントール
7.2.8. エベロリムス
7.2.9. その他
7.3. 電気刺激療法／神経調節療法)
7.3.1. 脳深部刺激療法（DBS）
7.3.2. 迷走神経刺激（VNS）
7.3.3. その他
7.4. その他
8. エンドユーザー別
8.1. 導入
8.1.1. 市場規模分析および前年比成長率分析(%), エンドユーザー別
8.1.2. 市場魅力度指数、エンドユーザー別
8.2. 病院・専門クリニック*市場
8.2.1. はじめに
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. 外来手術センター
8.4. その他
9. 地域別
9.1. 導入
9.1.1. 地域別市場規模分析および前年比成長率分析(%)
9.1.2. 市場魅力度指数、地域別
9.2. 北米
9.2.1. 序論
9.2.2. 主な地域別ダイナミクス
9.2.3. 市場規模分析および前年比成長率分析（%）、発作タイプ別
9.2.4. 市場規模分析および前年比成長率分析（%）、治療タイプ別
9.2.5. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
9.2.6. 市場規模分析および前年比成長率分析（%）, 国別
9.2.6.1. 米国
9.2.6.2. カナダ
9.2.6.3. メキシコ
9.3. ヨーロッパ
9.3.1. はじめに
9.3.2. 主な地域別動向
9.3.3. 市場規模分析および前年比成長率分析（%）、発作タイプ別
9.3.4. 市場規模分析および前年比成長率分析（%）、治療タイプ別
9.3.5. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
9.3.6. 市場規模分析および前年比成長率分析（%）, 国別
9.3.6.1. ドイツ
9.3.6.2. イギリス
9.3.6.3. フランス
9.3.6.4. スペイン
9.3.6.5. イタリア
9.3.6.6. その他のヨーロッパ
9.4. 南米
9.4.1. はじめに
9.4.2. 地域別主要市場
9.4.3. 市場規模分析および前年比成長率分析（%）、発作タイプ別
9.4.4. 市場規模分析および前年比成長率分析（%）、治療タイプ別
9.4.5. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
9.4.6. 市場規模分析および前年比成長率分析（%）, 国別
9.4.6.1. ブラジル
9.4.6.2. アルゼンチン
9.4.6.3. その他の南米諸国
9.5. アジア太平洋
9.5.1. はじめに
9.5.2. 主な地域別ダイナミクス
9.5.3. 市場規模分析および前年比成長率分析（%）、発作タイプ別
9.5.4. 市場規模分析および前年比成長率分析（%）、治療タイプ別
9.5.5. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
9.5.6. 市場規模分析および前年比成長率分析（%）, 国別
9.5.6.1. 中国
9.5.6.2. インド
9.5.6.3. 日本
9.5.6.4. 韓国
9.5.6.5. その他のアジア太平洋地域
9.6. 中東・アフリカ
9.6.1. 序論
9.6.2. 主な地域別ダイナミクス
9.6.3. 市場規模分析および前年比成長率分析（%）、発作タイプ別
9.6.4. 市場規模分析および前年比成長率分析（%）、治療タイプ別
9.6.5. 市場規模分析および前年比成長率分析（%）, エンドユーザー別
10. 競合情勢
10.1. 競争シナリオ
10.2. 市場ポジショニング／シェア分析
10.3. M&A分析
11. 企業プロフィール
11.1. Sanofi *
11.1.1. 会社概要
11.1.2. 製品ポートフォリオと内容
11.1.3. 財務概要
11.1.4. 主な展開
11.2. UCB S.A.
11.3. GLENMARK PHARMACEUTICALS LTD.
11.4. Marinus Pharmaceuticals, Inc.
11.5. Biocodex, Inc.
11.6. Teva Pharmaceuticals USA, Inc.
11.7. Novartis AG
11.8. Hikma Pharmaceuticals PLC
11.9. Lupin
11.10. Amneal Pharmaceuticals
リストは網羅的ではありません
12. 付録
12.1. アムニールについて
12.2. お問い合わせ

Overview
The global refractory epilepsy treatment market reached US$ 3.97 billion in 2023 and is expected to reach US$ 5.78 billion by 2031 growing with a CAGR of 4.8% during the forecast period 2024-2031.

Refractory epilepsy, often referred to as drug-resistant or intractable epilepsy, is a type of epilepsy characterized by the persistence of seizures that do not respond to treatment with at least two appropriately selected and tolerated antiepileptic drugs (AEDs). This condition impacts around 30-40% of people with epilepsy, resulting in considerable difficulties in treatment and a diminished quality of life.
People with epilepsy experience seizures due to abnormal communication between nerve cells in the brain, which leads to altered electrical activity. These seizures can vary in duration, lasting from just a few seconds to several minutes. Approximately one-third of individuals with epilepsy will eventually develop refractory epilepsy, a condition where standard medications fail to control their seizures effectively. Despite trying at least two different antiepileptic drugs (AEDs) that have been appropriately chosen and tolerated, the seizures persist.

Market Dynamics: Drivers
Rising incidence of epilepsy and increase in accidents and brain injuries
The demand for the global refractory epilepsy treatment market is driven by multiple factors. One of the key factors is the rising incidence of epilepsy and the increase in accidents and brain injuries. The global prevalence of epilepsy is on the rise, driven by a combination of factors such as an aging population, enhanced diagnostic technologies, and a greater occurrence of brain injuries. This increase in the number of people diagnosed with epilepsy, especially those with refractory epilepsy, highlights the critical demand for more effective treatment solutions for refractory epilepsy treatment.
The increase in accidents and brain injuries has led to a higher prevalence of post-traumatic epilepsy (PTE) and post-traumatic seizures (PTS). These conditions often result in refractory epilepsy, which is characterized by seizures that do not respond to standard anti-epileptic drugs (AEDs). As per The University of Chicago Medical Center data in December 2022, an estimated 65 million people globally have epilepsy, with 30% to 40% experiencing drug-resistant or medically refractory epilepsy, meaning they do not respond to standard anti-seizure medications.
The emergence of minimally invasive surgical techniques and advanced neuromodulation therapies marks a significant transformation in the treatment of drug-resistant epilepsy. These innovative approaches offer renewed hope for enhancing the quality of life and improving seizure management for many patients who previously had few effective options.

Restraints
Factors such as adverse effects associated with antiepileptic drugs, limited availability of treatment options, and complexity of drug-resistant epilepsy are expected to hamper the refractory epilepsy treatment market.

Segment Analysis
The global refractory epilepsy treatment market is segmented based on seizure type, treatment type, end-user, and region.
The drug type segment accounted for approximately 74.3% of the global refractory epilepsy treatment market share
The drug type segment is expected to hold the largest market share over the forecast period. The drug type segment in the global refractory epilepsy treatment market includes various medications specifically designed to manage drug-resistant epilepsy. Each of these drugs has unique mechanisms of action and indications, making them suitable for different patient needs.
As per NCBI research publication in January 2023, Vigabatrin is a medication utilized in the treatment and management of infantile spasms and refractory complex partial seizures. Classified as an anti-epileptic drug, it works by irreversibly inhibiting the enzyme responsible for breaking down gamma-aminobutyric acid (GABA), thereby increasing GABA levels in the brain.
According to the Neurological Research and Practice in February 2024, a research study stated that Four cases of refractory status epilepticus (SE) were successfully treated with fenfluramine. The refractory SE resolved within 4 to 7 days after initiating treatment with fenfluramine. The rapid up-titration of fenfluramine during the treatment was well tolerated by the patients.
Moreover, key player's product launches and approvals would drive this refractory epilepsy treatment market growth. For instance, in March 2022, UCB, a global biopharmaceutical company, announced that the FDA has approved FINTEPLA (fenfluramine) oral solution for treating seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged two years and older. Lennox-Gastaut syndrome is a severe form of childhood-onset epilepsy characterized by multiple types of seizures, often resistant to treatment. Patients typically experience drug-refractory seizures, leading to significant morbidity and serious impairments in neurodevelopment, cognitive abilities, and motor functions.

Geographical Analysis
North America accounted for approximately 44.3% of the global refractory epilepsy treatment market share
North America region is expected to hold the largest market share over the forecast period owing to the prevalence of epilepsy rising in North America, with around 3.4 million individuals affected in the U.S. This increase can be attributed to several factors, including an aging population, enhanced diagnostic capabilities, and a greater incidence of brain injuries. As more people are diagnosed with epilepsy, particularly those with drug-resistant forms, there is an escalating demand for effective treatment options.
Recent advancements in treatment approaches, including minimally invasive surgeries and neuromodulation therapies such as Vagus Nerve Stimulation (VNS) and Responsive Neurostimulation (RNS), are improving the management of refractory epilepsy. These innovative methods offer alternatives for patients who do not respond to conventional anti-epileptic drugs (AEDs).
Moreover, in this region, a major number of key players' presence, well-advanced healthcare infrastructure, government initiatives & regulatory support, and awareness programs, & funding and product approvals would propel this refractory epilepsy treatment market growth. For instance, in June 2024, in San Francisco, Neurona Therapeutics has recently announced that the FDA has granted its lead product candidate, NRTX-1001, the Regenerative Medicine Advanced Therapy (RMAT) designation for treating drug-resistant mesial temporal lobe epilepsy (MTLE).
NRTX-1001 signifies a potential transformative advancement in the treatment of drug-resistant epilepsy, particularly in cases where the conventional approach involves the surgical removal or ablation of the affected brain area.

Market Segmentation
By Seizure Type
• Primary/Generalized Seizures
• Partial/Focal Seizures
By Treatment Type
• Drug Type
o Vigabatrin
o Fenfluramine
o Rufinamide
o Ganaxolone
o Stiripentol
o Everolimus
o Others
• Electrical Stimulation/Neuromodulation Therapies)
o Deep Brain Stimulation (DBS)
o Vagus Nerve Stimulation (VNS)
o Others
• Others
By End-User
• Hospitals & Specialty Clinics
• Ambulatory Surgical Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o The rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape
The major global players in the refractory epilepsy treatment market include Sanofi, UCB S.A., GLENMARK PHARMACEUTICALS LTD., Marinus Pharmaceuticals, Inc., Biocodex, Inc., Teva Pharmaceuticals USA, Inc., Novartis AG, Hikma Pharmaceuticals PLC, Lupin, and Amneal Pharmaceuticals among others.

Key Developments
 In June 2024, EpilepsyGTx, a biotechnology firm dedicated to developing innovative gene therapies for focal refractory epilepsy, announced that it secured $10 million in seed funding. This financing round was led by the UCL Technology Fund, with additional participation from Health Technology Holding.

Why Purchase the Report?
• To visualize the global refractory epilepsy treatment
Market Segmentation based on seizure type, treatment type, end-user, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the refractory epilepsy treatment market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.
The global refractory epilepsy treatment market report would provide approximately 62 tables, 51 figures, and 183 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Seizure Type
3.2. Snippet by Treatment Type
3.3. Snippet by End-User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Incidence of Epilepsy and Increase in Accidents and Brain Injuries
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Adverse Effects Associated with the Antiepileptic Drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Seizure Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Seizure Type
6.1.2. Market Attractiveness Index, By Seizure Type
6.2. Primary/Generalized Seizures*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Partial/Focal Seizures
7. By Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.1.2. Market Attractiveness Index, By Treatment Type
7.2. Drug Type*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Vigabatrin
7.2.4. Fenfluramine
7.2.5. Rufinamide
7.2.6. Ganaxolone
7.2.7. Stiripentol
7.2.8. Everolimus
7.2.9. Others
7.3. Electrical Stimulation/Neuromodulation Therapies)
7.3.1. Deep Brain Stimulation (DBS)
7.3.2. Vagus Nerve Stimulation (VNS)
7.3.3. Others
7.4. Others
8. By End-User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals & Specialty Clinics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Ambulatory Surgical Centers
8.4. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Seizure Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Seizure Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Seizure Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Seizure Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Seizure Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Sanofi *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. UCB S.A.
11.3. GLENMARK PHARMACEUTICALS LTD.
11.4. Marinus Pharmaceuticals, Inc.
11.5. Biocodex, Inc.
11.6. Teva Pharmaceuticals USA, Inc.
11.7. Novartis AG
11.8. Hikma Pharmaceuticals PLC
11.9. Lupin
11.10. Amneal Pharmaceuticals
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us

*** 難治性てんかん治療の世界市場に関するよくある質問(FAQ) ***

・難治性てんかん治療の世界市場規模は？
→DataM Intelligence社は2023年の難治性てんかん治療の世界市場規模を39.7億米ドルと推定しています。

・難治性てんかん治療の世界市場予測は？
→DataM Intelligence社は2031年の難治性てんかん治療の世界市場規模を57.8億米ドルと予測しています。

・難治性てんかん治療市場の成長率は？
→DataM Intelligence社は難治性てんかん治療の世界市場が2024年～2031年に年平均4.8%成長すると展望しています。

・世界の難治性てんかん治療市場における主要プレイヤーは？
→「Sanofi, UCB S.A., GLENMARK PHARMACEUTICALS LTD., Marinus Pharmaceuticals, Inc., Biocodex, Inc., Teva Pharmaceuticals USA, Inc., Novartis AG, Hikma Pharmaceuticals PLC, Lupin, and Amneal Pharmaceuticalsなど ...」を難治性てんかん治療市場のグローバル主要プレイヤーとして判断しています。

※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、最終レポートの情報と少し異なる場合があります。

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/